There have been significant developments in robust tools for assessing outcome in psoriatic
arthritis. Since October 2002, much of the activity in this area has been developed by the …

A key objective of the assessment working group of the Group for Research and Assessment
of Psoriasis and Psoriatic Arthritis (GRAPPA) was to identify, develop, evaluate, and validate …

Several tools have been introduced in clinical trials to quantify the severity and the response
to a given therapeutic regimen of both psoriasis and psoriatic arthritis. Each method present …

Recent advances in biologic therapies have provided hope for patients with psoriatic arthritis
(PsA). However, studies have been hampered by the lack of acceptable and validated …

In order to measure disease activity, progression, and change with therapy in psoriatic
arthritis (PsA), it is important to use accurate, reliable, and feasible outcome measures that …

Outcome Measures in Rheumatology (OMERACT) conferences have developed a process
by which outcome measures to be included in clinical trials are identified by consensus …

In clinical practice, broad global assessments of psoriasis disease activity and its effect on
patients' quality of life are used to assess the severity of patients' disease and their response …

Psoriatic arthritis (PsA) is an important condition that significantly impacts affected patients.
The introduction of novel therapeutic agents for PsA has generated great interest in clinical …

Psoriatic arthritis is an inflammatory arthritis occurring in up to 30% of patients with psoriasis.
Its clear distinction from rheumatoid arthritis has been described clinically, genetically, and …

Historically, dermatologists and others looking after patients with psoriasis have tended to
record response to treatment, if at all, with rather imprecise phrases such as “nearly clear,”“a …